▲
STOCKUPSIDE.IO
Analyst Price Target Intelligence
← Full Rankings
← Back to rankings
Ranked #309 by analyst upside · 2026-06-27
CMPX
Compass Therapeutics, Inc.
Healthcare · Market Cap $375M · P/E 0x
ANALYST PRICE TARGET
+324.0%
implied upside to consensus target
Current Price $2.08
Consensus Target $8.82
Bull Target $24.0
Bear Target $4.0
Analysts Covering 11
ANALYST CONSENSUS — BUY
Strong Buy
2
Buy
9
Hold
0
Sell
0
52-Week Low $1.61
52-Week High $6.88
YTD Return -59.8%
FUNDAMENTALS
Market Cap $375M
P/E Ratio (TTM) N/A
Forward P/E -4.5x
EPS (TTM) $-0.40
PEG Ratio N/A
Dividend Yield N/A
Revenue (TTM) N/A
Profit Margin N/A
52-WEEK RANGE
52-Week Low $1.61
52-Week High $6.88
Current Price $2.08
Bear Target $4.0
Bull Target $24.0
● Now $2.08 ● Target $8.82
TRADING DATA
Avg Volume 7.9M
YTD Return -59.8%
Analyst Count 11
Consensus Buy
Upside to Target +324.0%
Last Updated 2026-06-27

ANALYST SUMMARY

Compass Therapeutics, Inc. (CMPX) is currently trading at $2.08 with a Wall Street consensus price target of $8.82, implying potential upside of 324.0% over the next 12 months. 11 analysts currently cover CMPX, with a consensus rating of Buy — 100% of analysts rate the stock a Buy or Strong Buy. The most bullish analyst has a price target of $24.0, while the most cautious has a target of $4.0.

CMPX operates in the Healthcare sector with a market capitalisation of $375M. The stock is down 59.8% year-to-date and is currently trading near the lower end of its 52-week range of $1.61 – $6.88.

SIMILAR STOCKS

Other Healthcare stocks with comparable size and valuation.

OMER +361.4%
Omeros Corporation
$627M · P/E 7.6x · Underperform
NAGE +268.4%
Niagen Bioscience, Inc.
$272M · P/E 16.3x · Buy
ABEO +251.4%
Abeona Therapeutics Inc.
$320M · P/E 5.9x · Buy
PLX +378.3%
Protalix BioTherapeutics, Inc.
$185M · P/E 12.1x · Buy
PALI +414.0%
Palisade Bio, Inc.
$328M · P/E 15.8x · Buy

RECENT ANALYST CALLS

Upgrade/downgrade history for CMPX, with each firm's 90-day track record across all stocks we track. See full firm rankings →

Canaccord Genuity — Reiterated
Buy → Buy 2026-04-28 Building track record
Citizens reit
Market Outperform → Market Outperform 2026-04-28 Building track record
HC Wainwright & Co. reit
Buy → Buy 2026-04-27 31% win rate (48 calls)
D. Boral Capital — Reiterated
Buy → Buy 2026-04-27 32% win rate (25 calls)
Guggenheim reit
Buy → Buy 2026-03-24 62% win rate (8 calls)
D. Boral Capital — Reiterated
Buy → Buy 2026-01-06 32% win rate (25 calls)
William Blair ● Initiated
Outperform 2026-01-05 44% win rate (9 calls)
Cantor Fitzgerald ● Initiated
Overweight 2025-12-03 40% win rate (10 calls)
HISTORICAL SNAPSHOT

Point-in-time data from StockUpside's daily snapshots. Tracks price, analyst target, upside %, consensus, and analyst count.

Loading…
ANALYST CONVICTION SCORE
—
out of 100
Coverage depth
0/30
Consensus clarity
0/30
Vote unanimity
0/25
Rating stability
0/15

Measures analyst agreement, not fundamental quality. A high score means analysts broadly agree on this call — not that the stock will go up.

See 4,000+ stocks ranked by analyst upside

StockUpside.io tracks analyst consensus price targets across thousands of US-listed stocks, updated every day. The full ranked list is available with a Pro subscription.

View Full Rankings →